![]() | |
Identifiers | |
---|---|
| |
CAS Number | |
PubChemCID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C18H24F2N2O |
Molar mass | 322.400 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
PF-03654746 is a potent and selectivehistamine H3 receptorantagonist developed byPfizer and currently undergoingclinical trials for the treatment ofADHD,Tourette syndrome[1] as well as potential anti-allergy applications.[2][3][4][5]
![]() | Thispharmacology-related article is astub. You can help Wikipedia byexpanding it. |